1000mg of (Hesperidin and Diosmin mixture) three times daily for 7 days 1000mg of (Hesperidin and Diosmin mixture) two times daily for 3 days

standard care therapy in quarantine hospitals

Coronavirus Infection

Hesperidin and Diosmin mixture

Hesperidin and Diosmin for Treatment of COVID-19

Randomized Double-blind Controlled Parallel Study of (Hesperidin and Diosmin Mixture) for Treatment of COVID-19 Newly Diagnosed Patients in Egypt

Prof. Dr. Kamal Mohammed Okasha

Professor

Tanta University

Randomized double-blind controlled Parallel study

Cardiac resynchronization therapy: Usual output programming

Cardiac resynchronization therapy: High output programming

Chronic Heart Failure

Cardiac resynchronization therapy

Leeds General Infirmary

Tailoring Pacemaker Output to Physiology in Chronic Heart Failure

KK Witte

Senior Lecturer in Cardiology

University of Leeds

Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Isoquercetin: 450 mg twice a day (at 08 a.m. and at 4 p.m).

Phase I Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 225mg twice a day (at 08 a.m. and at 4 p.m). Phase II Sunitinib: 50mg once daily orally schedule treatment according to Investigator's choice Placebo: 450 mg twice a day (at 08 a.m. and at 4 p.m).

Renal Cell Carcinoma

Kidney Cancer

Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)

Sunitinib

Isoquercetin: 225mg twice a day(at 08 a.m. and at 4 p.m)/Isoquercetin: 450 mg twice a day(at 08 a.m. and at 4 p.m).

Isoquercetin

Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).

Placebo

Ospedale Oncologico Regionale - Centro di Riferimento Oncologico di Basilicata U.O. di Oncologia Medica

Fondazione G. Pascale

University Federico II of Naples

Azienda Ospedaliera Cardarelli Divisione Di Oncologia

Azienda Ospedaliera Ruggi Aragona

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial

To evaluate the activity of isoquercetin as an anti-fatigue agent in patients with kidney cancer receiving sunitinib by using the FACT-F questionnaire after 2 sunitinib cycles.

• The maximum tolerated dose (450/900 mg daily) of isoquercetin administered concomitantly with sunitinib is the primary end point of the phase I part of the trial;

To evaluate the effect of isoquercetin on quality of life as assessed by the FACT-G score

To evaluate the effect of isoquercetin on serum markers of inflammation (C reactive protein, IL-6, IL10)

To evaluate the effect of isoquercetin on dose density and patient compliance

To evaluate the effect of isoquercetin on muscle index using CT scans

Incidence of deep venous thrombosis, as assessed by doppler ultrasound

To evaluate the effect of isoquercetin on patient compliance will be used a questionnaire

glycoside/fatigue

Hesperidin and Diosmin for Treatment of COVID-19

Tailoring Pacemaker Output to Physiology in Chronic Heart Failure

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial

The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy

La base de données d'herbes médicinales la plus complète soutenue par la science